Efficacy of Different Second-line Therapy Regimens in Metastatic Urothelial Carcinoma

Lukas Barwitz, A. Berger, Stefanie Zschaebitz, M. Jenzer, C. Nientiedt, S. Duensing, D. Jäger, D. Teber, M. Hohenfellner, C. Grüllich
{"title":"Efficacy of Different Second-line Therapy Regimens in Metastatic Urothelial Carcinoma","authors":"Lukas Barwitz, A. Berger, Stefanie Zschaebitz, M. Jenzer, C. Nientiedt, S. Duensing, D. Jäger, D. Teber, M. Hohenfellner, C. Grüllich","doi":"10.2174/1874303X01710010052","DOIUrl":null,"url":null,"abstract":"Results: Median overall survival (OS) from first line therapy over all lines was 28,0 months. Median OS from second line was 14,7 months (95% CI, 11,4-18,0). No significant differences between regimens could be detected. OS of patients with lymphonodal only involvement (n=16, 22,5%) was 35.5 months (95% CI 0.0-73.9), OS with visceral metastases excluding liver was 14.7 months (95% CI 9.8-19.6) .and OS with any liver involvement was 9.4 months (95% CI 0.0-20.9).","PeriodicalId":38952,"journal":{"name":"Open Urology and Nephrology Journal","volume":"10 1","pages":"52-58"},"PeriodicalIF":0.0000,"publicationDate":"2017-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Urology and Nephrology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874303X01710010052","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Results: Median overall survival (OS) from first line therapy over all lines was 28,0 months. Median OS from second line was 14,7 months (95% CI, 11,4-18,0). No significant differences between regimens could be detected. OS of patients with lymphonodal only involvement (n=16, 22,5%) was 35.5 months (95% CI 0.0-73.9), OS with visceral metastases excluding liver was 14.7 months (95% CI 9.8-19.6) .and OS with any liver involvement was 9.4 months (95% CI 0.0-20.9).
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
不同二线治疗方案对转移性尿路上皮癌的疗效
结果:一线治疗的中位总生存期(OS)为280个月。二线的中位OS为14.7个月(95% CI, 11,4-18,0)。两种治疗方案之间未发现显著差异。仅淋巴结受累(n=16、22、5%)患者的生存期为35.5个月(95% CI 0-73.9),不包括肝脏的内脏转移的生存期为14.7个月(95% CI 9.8-19.6),任何肝脏受累的生存期为9.4个月(95% CI 0-20.9)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.30
自引率
0.00%
发文量
7
期刊最新文献
Does Circumplast Ring Offer Safe Alternative to Standard Plastibell Ring for Infant Male Circumcision? Survival and Analysis of Predictors of Mortality in Patients Undergoing Hemodialysis in a Rural Hospital in Puducherry, India: A Retrospective Cohort Study Parameters of Chronic Kidney Disease to Identify Outpatients at Increased Risk for COVID-19 Mortality: A Cohort Study of UK Biobank Participants Accuracy of Bioimpedance Modalities for Fluid Assessment in Hemodialysis Patients: A Randomized Observational Study Treatment of Acute Antibody-Mediated Rejection in Children Post-Kidney Transplantation: A Single Center’s Experience
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1